Sarepta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.
The next presenting company is Sarepta. And speaking on behalf of the company, we have CEO, Doug Ingram. Before I turn it over to Doug, just wanted to highlight for those listeners on the webcast to please use the submit-a-question, ask-a-question button in the portal, and I'm happy to ask the question on your behalf. Doug, take it away.
Thank you very much, Anupam. Let's pull the slide deck up now. Great. And good morning to everyone online, and thank you for joining us today. As a mission-driven leader in precision genetic medicine for rare disease with a pipeline of over 40 candidates across RNA and gene therapy and gene editing, there is much that we can discuss today.
However, in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |